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& Abstract
Background: Remifentanil has been associated with
increased acute and potentially chronic postoperative pain.
The objective of this prospective randomized controlled trial
was to investigate the influence of intraoperative remifentanil
on acute and chronic postoperative pain after cardiac surgery.
Methods: Patients (N = 126) receiving standardized anes-
thesia with propofol and intermittent intravenous fentanyl
at predetermined times for cardiac surgery were randomized
to intraoperatively receive either a continuous remifentanil
infusion or additional intermittent intraoperative fentanyl as
needed. The primary endpoint was chronic thoracic pain at
12 months after surgery. Secondary endpoints were pain at 3
and 6 months after surgery and analgesic requirements and
pain levels in the first 72 hours.
Results: There was no significant difference in incidence of
chronic thoracic pain between the remifentanil and fentanyl
groups, respectively (20% vs. 18%; P = 0.817). At 3 months,
however, significantly more patients in the remifentanil
group reported chronic thoracic pain (51% vs. 33%;
P = 0.047). This effect was more pronounced in younger
patients and in patients receiving a higher dose of remifen-
tanil (both P < 0.05). The first 24 and 48 hours postopera-
tively, morphine consumption in the remifentanil group was
significantly higher than in the fentanyl group (34.3 mg
[interquartile range (IQR) 25.3 to 48.2] vs. 30.2 mg [IQR 19.2
to 38.1], P = 0.028; and 46.8 mg [IQR 33.8 to 59.2] vs. 39.0 mg
[IQR 6.2 to 51.4], P = 0.047, respectively).
Conclusions: Intraoperative use of remifentanil during car-
diac surgerydoes not impact chronicpostoperativepain 1 year
after surgery. Nevertheless, remifentanil increases analgesic
requirements and thoracic pain until 3 months after surgery,
and itsuse is therefore less favorableduringcardiac surgery. &
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INTRODUCTION
Opioids are part of the multimodal anesthesia regimen
for the management of pain during and after surgery.
One of these opioids, remifentanil, is often used because
of its favorable pharmacokinetic and pharmacodynamic
properties, including fast onset and offset of action,
predictable rapid recovery profile independent of infu-
sion duration, and metabolism independent of kidney or
liver function.1,2
Recently, however, opioids, and remifentanil in
particular, have been associated with opioid-induced
hyperalgesia, or acute opioid tolerance.1,3 Concerning
remifentanil, its ultra-short half-life, resulting in abrupt
analgesic offset after cessation of the infusion, is
thought to contribute to high postoperative pain
levels.1 Still, the clinical impact of these higher levels
in the short term, but particularly in the long term, is
not clear.4–6.
In recent years, more attention has been focused on
the risk for chronic pain after surgery.7,8 The Interna-
tional Association for the Study of Pain defines chronic
postoperative pain as pain that develops after surgical
intervention and lasts at least 2 months while other
causes of pain have been excluded.9 Specifically for
cardiac surgery, where the incidence of chronic postop-
erative pain is relatively high,10 intraoperative use of
remifentanil has been associated with chronic thoracic
pain.11,12 In a randomized study designed to evaluate
the occurrence of chronic thoracic pain after cardiac
surgery, remifentanil was combined with epidural anes-
thesia. The incidence of chronic pain in the high-dose
remifentanil group was significantly higher than in the
low-dose group.12 In another observational study in 90
cardiac surgery patients, intraoperative remifentanil was
predictive for chronic thoracic pain in a dose-dependent
manner.11 However, this study was not designed to
investigate the role of remifentanil in chronic pain after
surgery.
Therefore, we performed a prospective randomized
controlled trial investigating the influence of intraop-
erative remifentanil administration during cardiac
surgery on the development chronic thoracic pain
after surgery. For this purpose, we randomized
between 2 standard care regimens in our hospital
and collected data on chronic postoperative pain and
quality of life 3, 6, and 12 months after surgery. In
addition, acute pain was evaluated by collecting pain




This study is a prospective, randomized, single-blind
clinical trial of which the study protocol has been
published previously.13 The study was approved by the
local research ethics committee and registered at Clin-
icalTrials.gov (NCT02031016). Patients were included
from February until November 2014. Written informed
consent was obtained from all subjects. Eligible patients
were randomly assigned 1:1 (using computerized ran-
dom numbers) to either the remifentanil or the fentanyl
study arm and blinded for treatment group allocation.
Inclusion criteria were: (1) patients undergoing cardiac
surgery via sternotomy (a coronary artery bypass graft
and/or valve replacement); (2) age between 18 and
85 years; and (3) weight between 45 and 140 kg.
Exclusion criteria were: (1) pregnancy or breastfeeding;
(2) language barrier; (3) history of drug abuse; (4)
neurologic condition such as peripheral neuropathy or
fibromyalgia; (5) known remifentanil, fentanyl, mor-
phine, or paracetamol allergy; (6) body mass index
above 35 kg/m2; (7) prior cardiac surgery (reopera-
tions); or (8) chronic pain condition.
Intraoperative Anesthesia and Analgesia
Premedication and induction of anesthesia were stan-
dardized in all patients. Both groups then received a
continuous infusion of propofol (starting dose 200 to
300 mg/hour) and intermittent intravenous fentanyl
(500 lg) at predetermined times (ie, before incision, at
sternotomy, at aorta cannulation, and at opening of the
pericardium). At the discretion of the attending anes-
thesiologist, the dose of fentanyl could be reduced to a
minimum of 200 lg depending on patient characteris-
tics (eg, old age, hemodynamics, low body weight,
ejection fraction). Patients in the remifentanil group
received a continuous infusion of remifentanil (starting
dose 0.15 lg/kg/ideal body weight/minute) in addition
to the propofol and predetermined fentanyl anesthetic
regimen. The remifentanil starting dose could be
adjusted at the discretion of the anesthesiologist.
Patients in the fentanyl group received additional
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boluses of fentanyl if predetermined fentanyl doses were
insufficient. The attending anesthesiologist decided,
based on patient characteristics (eg, sweating, hemody-
namics, body weight, ejection fraction), if extra fentanyl
(200 to 500 lg) was indicated. In both groups, sevoflu-
rane was used as needed, and no nitrous oxide was used.
In both groups, patients received 5 or 10 mg of
intravenous morphine (depending on hemodynamic
status) 30 minutes before the anticipated end of surgery.
Postoperative Pain Measurement and Analgesia
After surgery, patients were first admitted either to the
intensive care unit (ICU) or postanesthesia care unit
(PACU). These units and the general postoperative
ward use the same standardized postoperative treat-
ment.14,15 Numeric rating scale (NRS) pain scores (0 to
10) were collected at least 3 times a day by the nursing
staff on the ICU/PACU or ward. Immediately after
surgery, 1 g of oral or intravenous paracetamol was
given 4 times a day together with a continuous infusion
of morphine (starting dose 2 mg/hour), which was
adapted individually on the guidance of the patient’s
NRS pain scores. A pain titration protocol was used,
with a targeted NRS value of < 4. Analgesics were
increased after patients reported an NRS score of ≥4
and decreased after patients reported an NRS score of 0
or 1.15 The continuous infusion of morphine was
stopped upon transfer to the general postoperative
ward and replaced by 2.5 to 10 mg of (intravenous)
morphine on demand. Paracetamol (1 g oral or intra-
venous) 4 times a day was continued until discharge.
On the ward, patients could receive oxycodone or
tramadol orally, which was calculated to morphine
equivalents. Consumption of opioids was calculated per
24 hours until 72 hours after surgery.
Study Endpoints
The primary endpoint of this study was chronic
postoperative pain, which was evaluated at 12 months
after cardiac surgery. Chronic thoracic pain was defined
as sternal and/or thoracic pain (NRS score > 0) that the
patient identified as related to surgery and that was
different from angina.16 Chronic thoracic pain was
measured with a questionnaire based on the Brief Pain
Inventory17 and described previously.16 The question-
naire was sent by regular mail or e-mail. Secondary
outcomes were chronic pain at 3 and 6 months after
surgery, opioid consumption during the first 72 hours
after surgery, and health-related quality of life at 3, 6,
and 12 months after surgery.
Quality of life was measured using the physical
composite score (PCS) and the mental composite score
(MCS) of the short form (SF)-12 health status instru-
ment, both ranging from 0 to 100, with higher scores
representing higher levels of functioning.18 Dutch age-
and sex-standardized population norms are available
elsewhere.19.
Statistical Analysis
The planned statistical analyses have been described
previously.13 We determined that a sample size of 126
patients would provide a power of 80% to detect a 20%
absolute reduction in the primary outcome from a
baseline risk of 30%, at a 2-sided alpha level of 0.05.11
All analyses were performed according to the intention-
to-treat principle. We used the chi-square test or Fisher’s
exact test to analyze categorical variables and Student’s
t-test or the Mann-Whitney test for continuous vari-
ables. The Kolmogorov-Smirnov test together with
visual inspection of the histograms were used to assess
whether the variables were normally distributed. Odds
ratios (ORs) and 95% confidence intervals (CIs) were
calculated to quantify risk. Imbalance (if any) in the
baseline characteristics was approached from a clini-
cian’s and literature perspective and statistically tested
through assessment of the impact on the coefficient of
the treatment allocation in a multivariable logistic
regression analysis. Post hoc, we have also explored
(1) the potential effect modification by testing the
significance of an interaction term with age in our
multivariable logistic regression model and (2) a poten-
tial dose-related effect of remifentanil by replacing the
dichotomous treatment allocation variable by a cate-
gorical variable (fentanyl, low-dose remifentanil, high-
dose remifentanil). A sensitivity analysis was conducted
by exclusion of patients with missing data at any of the
intermediate follow-up time points. The statistical
analyses were conducted with the SPSS statistical
package (version 24.0 for Windows; SPSS, Chicago,
IL, U.S.A.). All statistical tests were 2-sided and used a
significance level of 0.05.
RESULTS
Figure 1 shows the randomization and flow of patients
in the trial; of the 555 patients screened for eligibility,
128 patients signed informed consent, of which 2 were
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excluded later because of the exclusion criteria (1
patient’s surgical procedure was altered to a noninvasive
approach and 1 patient appeared to have had prior
cardiac surgery). Table 1 describes the characteristics of
the remaining 126 patients. A total of 122 patients
(96.8%) filled out the questionnaire 12 months after the
study; 2 patients died, and contact was lost with 2 other
patients. All analyses for the primary outcome were
based on the data from these 122 patients.
Outcomes
The primary outcome, chronic thoracic pain 12 months
after surgery, was not significantly different between the
remifentanil and fentanyl groups, respectively (20% vs.
18%; P = 0.817; OR 0.9; 95% CI 0.4 to 2.2) (Table 2).
Regarding physical and mental composite scores of
quality of life 1 year after surgery (secondary outcome),
no differences between the remifentanil and fentanyl
groups, respectively, were found (PCS 57.0 [interquar-
tile range (IQR) 53.3 to 59.6] vs. 56.9 [IQR 51.2 to
58.8], P = 0.459; MCS 55.2 [IQR 50.7 to 58.1] vs. 55.7
[IQR 52.2 to 58.6], P = 0.596) (see Table 2). In the
group of 23 patients who reported pain 12 months after
surgery, pain levels were not significantly different
between the remifentanil and fentanyl groups, respec-
tively, on an average day (4.0 [IQR 2.0 to 4.0] vs. 3.0
[IQR 1.3 to 5.8]; P = 0.708), good day (2.0 [IQR 1.0 to
4.0] vs. (0.0 [IQR 0.0 to 3.0]; P = 0.113), or bad day
(5.0 [IQR 2.0 to 7.0] vs. 3.5 [IQR 1.3 to 5.8];
P = 0.226). Type of pain was comparable between the
remifentanil and fentanyl groups, respectively, and was
mostly described as sharp pain (36.4% vs. 41.7%) or
pressure pain (36.4% vs. 33.3%). Pain was mostly
localized around the site of incision in both the
remifentanil group and the fentanyl group, respectively
(63.6% vs. 41.7%; P = 0.524). No significant differ-
ences were found between pain characteristics at differ-
ent time points (see Table S1 in the Supplementary
Appendix).
Figure 2 shows the percentage of patients reporting
thoracic pain after 3, 6, and 12 months. The proportion
of patients reporting thoracic pain after 3 months was
significantly higher in the remifentanil compared to the
fentanyl group, respectively (51% vs. 33%; P = 0.047;
OR 2.1; 95% CI 1.0 to 4.2). The effect was not different
at 6 months (32% vs. 27%; P = 0.556; OR 0.8; 95%CI
0.4 to 1.7).
During the first 24 and 48 hours after surgery, the
median consumption of opioids in the remifentanil
group was significantly higher than in the fentanyl
group, respectively (34.3 mg [IQR 25.3 to 48.2] vs.
30.2 mg [IQR 19.2 to 38.1], P = 0.028; and 46.8 mg
[IQR 33.8 to 59.2] vs. 39.0 mg [IQR 26.2 to 51.4],
P = 0.047) (Figure 3). This cumulative difference in
opioid consumption was not significantly different at
Figure 1. Consort diagram with the
flow of the patients in the study.
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72 hours after surgery (48.3 mg [IQR 34.7 to 62.2] vs.
43.0 mg [IQR 27.9 to 76.3]; P = 0.162). This difference
in opioid consumption led to no significant difference
(P > 0.05) in pain scores (NRS) the first 72 hours after
surgery (see Table S2 in the Supplementary Appendix).
There was no significant difference between the amount
of morphine given at the anticipated end of surgery
(10.0 mg [IQR 10.0 to 10.0] vs. 10.0 [IQR 10.0 to
10.0]; P = 0.953).
Because there was a 4-year difference in mean age
(66 years vs. 62 years, P = 0.007) between the remifen-
tanil and fentanyl groups, respectively, we explored the
impact of imbalanced age in a multivariable logistic
regression analysis. In that analysis, age altered the
coefficient of treatment allocation by more than 10%,
resulting in an adjusted OR of 0.6 (95% CI 0.2 to 1.7;
P = 0.362).
In a post hoc analysis, effect modification by age was
not significant 12 months after surgery. No significant
difference of chronic pain 12 months after surgery was
found between patients < 65 years of age (adjusted OR
1.1; 95% CI 0.3 to 3.7; P = 0.920) and patients
≥65 years of age (adjusted OR 0.4; 95% CI 0.1 to 2.1;
Table 2. Chronic Thoracic Pain and Quality of Life at 3, 6, and 12 Months
Fentanyl Remifentanil RR (95% CI) P Value
Chronic thoracic pain (n, %)
3 months (n = 126) 21 (33%) 32 (51%) 2.1 (1.0 to 4.2) 0.047
6 months (n = 124) 20 (32%) 17 (27%) 0.8 (0.4 to 1.7) 0.556
12 months (n = 122) 12 (20%) 11 (18%) 0.9 (0.4 to 2.2) 0.817
Quality of life (median, IQR)
3 months (n = 126)
PCS 55.0 (46.9 to 58.3) 55.4 (49.3 to 58.8) 0.971
MCS 51.4 (47.9 to 55.6) 54.0 (48.7 to 57.4) 0.325
6 months (n = 124)
PCS 56.0 (50.4 to 58.1) 55.9 (48.5 to 58.8) 0.901
MCS 53.2 (49.3 to 57.5) 54.4 (49.3 to 57.4) 1.0
12 months (n = 122)
PCS 56.9 (51.2 to 58.8) 57.0 (53.3 to 59.6) 0.459
MCS 55.7 (52.2 to 58.6) 55.2 (50.7 to 58.1) 0.596
Continuous data are expressed as means (standard deviation) or medians (interquartile range), and categorical data are expressed as number (%).
95% CI, 95% confidence interval; IQR, interquartile range; NRS, numeric rating scale; MCS, mental composite score; PCS, physical composite score.
Figure 2. Chronic postoperative pain reported 3, 6, and
12 months after surgery in the fentanyl group (solid black)
compared to the remifentanil group (grey). *P = 0.047.






Male gender 57 (90%) 58 (92%)
Age (years) 66 (7.6) 62 (9.0)
BMI (kg/m2) 28.0 (3.1) 27.5 (3.6)
Preoperative NRS score 0 (0 to 0) 0 (0 to 0)
Preoperative quality of life score
PCS 49.3 (43.3 to 53.1) 47.6 (39.6 to 54.3)
MCS 51.3 (46.1 to 57.2) 50.4 (46.8 to 54.3)
Type of surgery
CABG 51 (81%) 49 (78%)
Valve 9 (14%) 7 (11%)
Combination 3 (5%) 7 (11%)
euroSCORE 3 (2 to 4) 2 (0 to 4)
Duration of
anesthesia (minutes)
218.6 (49.0) 233.4 (72.1)
Duration of
surgery (minutes)
187.4 (46.7) 198.1 (70.8)
Mechanical
ventilation (hours)
10.8 (4.5) 13.3 (23.8)
Intraoperative use of analgesics/sedatives
Sevoflurane
Minutes 32.8 (23.1) 32.4 (24.8)
MAC 0.34 (0.1) 0.33 (0.1)
End tidal 0.69 (0.3) 0.67 (0.3)
Propofol (mg/kg) 13.1 (4.4) 13.3 (6.9)
Fentanyl (lg/kg) 26.1 (9.0) 21.8 (7.8)
Remifentanil (lg/kg) NA 25.1 (8.9)
Total remifentanil (lg) NA 2165.0 (696.0)
Patients admitted to PACU 35 (56%) 41 (65%)
Length of hospital stay (days) 5.0 (3.0 to 7.0) 5.0 (3.0 to 7.0)
Length of stay in
the ICU/PACU (hours)
19.5 (16.7 to 22.4) 19.6 (16.2 to 21.4)
Continuous data are presented as means (standard deviation) or medians (interquartile
range), and categorical data are presented as number (%).
BMI, body mass index; CABG, coronary artery bypass grafting; MAC; minimum alveolar
concentration; NRS, numeric rating scale; IQR, interquartile range; PCS, physical
composite score; MCS, mental composite score; PACU, postanesthesia care unit; ICU,
intensive care unit.
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P = 0.281). No dose-related effect of remifentanil on
chronic pain 12 months after surgery was found.
Regarding the secondary endpoints, age was found to
be an effect modifier through an interaction term
(P = 0.052). This resulted in a significant effect of
remifentanil on chronic thoracic pain after 3 months for
patients < 65 years of age (adjusted OR 4.0; 95%CI 1.3
to 12.2; P = 0.016) and no effect in patients ≥65 years
of age (adjusted OR 0.9; 95% CI 0.3 to 2.5; P = 0.856).
This effect of age was absent 6 months after surgery. A
dose-related effect of remifentanil on pain after
3 months with ORs of 1.3 (95% 0.5 to 3.1) and 3.3
(95% CI 1.4 to 8.1) was also observed for a cumulative
dose of < 1,875 lg and ≥ 1,875 lg, respectively. This
dose-related effect was absent for the outcome of
chronic pain 6 months after surgery. The sensitivity
analysis excluding patients with missing data at any of
the time points resulted in very similar results compared
to the original analyses (see Table S3 in the Supplemen-
tary Appendix).
DISCUSSION
This randomized single-blind controlled trial showed
that the use of remifentanil during cardiac surgery does
not lead to an increased incidence of chronic thoracic
pain 12 months after surgery. Considering the short-
term effects, remifentanil was associated with a small,
but significant, increase in postoperative opioid con-
sumption during the first 48 hours after cardiac surgery.
In addition, more patients in the remifentanil group
developed chronic thoracic pain at the site of surgery
after 3 months, and this effect proved to be age
dependent and dose related.
To start, this study showed no significant increase in
chronic thoracic pain 12 months postoperatively for
remifentanil compared to fentanyl, even though a
significant difference in reported thoracic pain was
observed 3 months after surgery (see Figure 2). The
latter suggests alteration of pain sensitivity caused by
remifentanil. Our finding that chronic pain was espe-
cially observed in patients receiving a higher dose of
remifentanil further supports this. A dose-dependent
relationship is also in line with previous reports.11,20,21
A few other studies have suggested an effect of
remifentanil on chronic pain. Salengros et al.12 con-
cluded that high-dose remifentanil plus postsurgical
epidural analgesics resulted in higher incidences of
chronic pain after cardiac surgery compared to preop-
erative epidural analgesics and low-dose remifentanil
during surgery. In another observational, nonrandom-
ized study, remifentanil proved to be a risk factor for the
development of chronic pain at 12 months in a dose-
dependent manner.11 In contrast to our study, these
studies were not designed to measure the effect of
remifentanil on chronic postoperative pain and/or post-
operative analgesics.
Generally stated, the mechanisms of postprocedural
pain and chronic postsurgical pain are complex and
poorly understood. Nerve injury or inflammatory reac-
tions after surgery causing central sensitization are
suggested as causes of postsurgical pain.22 Modulation
or increased activity of N-methyl-D-aspartate (NDMA)
receptors have been hypothesized to lead to inflamma-
tory and neuropathic pain states,23 and possibly activa-
tion and exacerbation of hyperalgesia.24 It is known that
remifentanil affects the NMDA receptor directly or
indirectly,23,25 which as such could influence the devel-
opment of acute and chronic pain. This effect of
remifentanil on the NMDA receptor could explain the
higher morphine consumption immediately postsurgery
and the higher incidence of chronic thoracic pain after
3 months in the remifentanil group. In addition, age-
related alterations of NMDA receptors26,27 and
decreased neuroplasticity in the elderly could explain
the relatively lower sensitivity to the effects of remifen-
tanil at higher age, found in this study. This finding
requires further exploration as this subgroup analysis
was not predefined.
In this study we quantified acute postoperative pain
on the basis of the need for postoperative opioids in the
first 72 hours, as was done in previous studies.3,4,28,29
All patients received, besides a morphine loading dose
on the operating room at the end of surgery, a
continuous morphine infusion that was subsequently
adapted on the guidance of individual pain scores. The
Figure 3. Cumulative opioid consumption 24, 48, and 72 hours
postoperatively in the fentanyl group (solid black) compared to
the remifentanil group (grey). *P = 0.028; **P = 0.047.
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ICU and PACU in our hospital were the settings for this
study, with a pain management protocol that has been in
place for years14 allowing for randomized controlled
trials and related studies.15,30,31 In this setting, patients
receiving intraoperative remifentanil received signifi-
cantly more morphine after 48 hours postsurgery com-
pared to patients receiving intraoperative fentanyl,
which implies that patients in the remifentanil group
requested more pain relief. While the difference between
the groups is statistically significant, the absolute
difference is very small and most likely not of clinical
consequence as there are no safety issues involved with
these amounts of morphine. Still, other studies have also
reported an association between the administration of
intraoperative remifentanil and an increase in consump-
tion of postoperative analgesics during the first 24 or 48
postoperative hours.20,21,32–34 Compared to these
reports, our study was the first randomized controlled
trial that also investigated and reported chronic thoracic
pain.
In times of cost containment in health care, remifen-
tanil has, due to its favorable pharmacokinetic profile,
received special interest in fast-track cardiac surgery.
The use of remifentanil potentially reduces the time on
mechanical ventilation and length of hospital stay.35
However, when reviewed from a patient point of view,
the advantages of remifentanil are questionable. In
addition to worse pain outcomes, postoperative cogni-
tive dysfunction and recovery after fast-track surgery
were not improved when remifentanil was compared to
long-acting sufentanil.36,37 In light of these results,
clinicians should outweigh the proposed benefits of
remifentanil against the suggested negative impact for
the patients, such as the impact on postoperative pain,
knowing that several alternatives for remifentanil are
available and that a lower dose of remifentanil decreases
the risk for development of chronic pain during the first
couple of months. Cardiac surgery is major surgery with
a high incidence of chronic postoperative pain; there-
fore, remifentanil may not be the ideal opioid for this
kind of surgery.
Some limitations of our study should be addressed.
First, as pointed out in our study protocol,13 ideally, the
study design should be double blind and contain no
other opioid besides remifentanil. However, since
patients themselves report postoperative pain scores,
which in turn guide morphine administration, we felt
that with blinding the patients only, adequate blinding
for the main endpoint was already preserved. Moreover,
a double-blind, double-dummy trial is not only labor
intensive, but also expensive. In addition, a study arm
without opioids is obviously unethical, and therefore we
chose a design that had been described previously.11 In
this design, we decided not to compare fentanyl with a
study arm with only short-acting remifentanil since it
was expected that high doses of remifentanil would be
needed in this painful and extended procedure. In our
study, increased analgesic consumption in the remifen-
tanil group was found, which was in accordance with
other studies with different control groups,20,21,38
although in those reports it could not be excluded that
results were subject to selection bias. Last, sample size
calculation was based on a reduction of the primary
outcome from 30% to 10%, based on a previous
observational study.11 In our present study, the inci-
dence of chronic postoperative pain was around 20% in
both study arms, suggesting that other factors besides
remifentanil might have been responsible for the
increased risk for thoracic pain in the observational
study. It might be possible that the calculated sample
size for primary outcome may provide insufficient
statistical power to detect clinically relevant differences
on secondary outcome parameters such as pain scores.
In conclusion, remifentanil administration during
cardiac surgery does not impact chronic postoperative
pain 1 year after surgery. In the shorter term, remifen-
tanil increases the need for opioid consumption postop-
eratively and leads to higher incidence of chronic
thoracic pain 3 months after surgery. This negative
impact in the shorter term makes remifentanil less
favorable for prolonged surgery such as cardiac surgery.
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